Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
May 1, 2024
Compelling study showing Asciminib vs. investigator’s choice TKi. Asciminib was better tolerated and with deeper molecular responses. This may become a preferred option for many new chronic myeloid leukemia (CML) patients. Cost may be an issue.
